Strikingly, even amidst high levels of PD-L1 expression and an elevated TMB, CDKN2A LOF was linked to suboptimal outcomes following immunotherapy in NSCLC patients (36). The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.